,address1,address2,city,country,phone,fax,website,industry,sector,longBusinessSummary,fullTimeEmployees,companyOfficers,auditRisk,boardRisk,compensationRisk,shareHolderRightsRisk,overallRisk,governanceEpochDate,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,sharesShort,sharesShortPriorMonth,sharesShortPreviousMonthDate,dateShortInterest,sharesPercentSharesOut,heldPercentInsiders,heldPercentInstitutions,shortRatio,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,lastSplitFactor,lastSplitDate,enterpriseToRevenue,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,recommendationMean,recommendationKey,numberOfAnalystOpinions,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,totalRevenue,debtToEquity,revenuePerShare,returnOnAssets,returnOnEquity,grossProfits,freeCashflow,operatingCashflow,revenueGrowth,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,Cheung Kong Center,48th Floor 2 Queen's Road,Central,Hong Kong,852 2121 8200,852 2128 1778,https://www.hutch-med.com,Drug Manufacturers—Specialty & Generic,Healthcare,"HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3'-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton's tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; HMPL-A83, an investigational IgG4-type humanized anti-CD47 monoclonal antibody; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. The company was incorporated in 2000 and is headquartered in Central, Hong Kong.",1990,"{'maxAge': 1, 'name': 'Mr. Chi Keung  To ACGI, B.Sc., BSc, M.B.A., MBA', 'age': 70, 'title': 'Exec. Chairman', 'yearBorn': 1952, 'fiscalYear': 2022, 'totalPay': 85000, 'exercisedValue': 0, 'unexercisedValue': 0}",2,3,7,4,5,1693526400,1672444800,86400,2,14.7,14.89,14.56,15.025,14.7,14.89,14.56,15.025,0.0,0.872372,-14.144232,162843,162843,109469,97700,97700,14.5,14.78,1000,1100,2572484864,7.39,21.28,3.3972037,14.0608,14.5965,0.0,0.0,USD,1695426048,-0.03885,92471474,174198000,927979,1035902,1690761600,1693440000,0.0053,0.00413,0.14908,8.71,4.61,3.1908894,1672444800,1703980800,1688083200,-29423000,-0.25,-1.04,1:1,1559174400,2.239,-18.593,NMS,EQUITY,HCM,HCM,HUTCHMED (China) Limited,HUTCHMED (China) Limited,1458135000,America/New_York,EDT,-14400000,14.71,50.0,14.6,31.08,28.6,2.0,buy,10,858443008,5.06,-91185000,40147000,3.006,3.199,757235968,5.018,4.475,-0.04981,-0.03396,-271587000,-91008128,47663000,1.637,0.033469997,-0.12042,-0.13112001,USD,
1,Cheung Kong Center,48th Floor 2 Queen's Road,Central,Hong Kong,852 2121 8200,852 2128 1778,https://www.hutch-med.com,Drug Manufacturers—Specialty & Generic,Healthcare,"HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3'-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton's tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; HMPL-A83, an investigational IgG4-type humanized anti-CD47 monoclonal antibody; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. The company was incorporated in 2000 and is headquartered in Central, Hong Kong.",1990,"{'maxAge': 1, 'name': 'Dr. Wei-Guo  Su B.Sc., Ph.D.', 'age': 64, 'title': 'CEO, Chief Scientific Officer & Exec. Director', 'yearBorn': 1958, 'fiscalYear': 2022, 'totalPay': 1972000, 'exercisedValue': 0, 'unexercisedValue': 2421833}",2,3,7,4,5,1693526400,1672444800,86400,2,14.7,14.89,14.56,15.025,14.7,14.89,14.56,15.025,0.0,0.872372,-14.144232,162843,162843,109469,97700,97700,14.5,14.78,1000,1100,2572484864,7.39,21.28,3.3972037,14.0608,14.5965,0.0,0.0,USD,1695426048,-0.03885,92471474,174198000,927979,1035902,1690761600,1693440000,0.0053,0.00413,0.14908,8.71,4.61,3.1908894,1672444800,1703980800,1688083200,-29423000,-0.25,-1.04,1:1,1559174400,2.239,-18.593,NMS,EQUITY,HCM,HCM,HUTCHMED (China) Limited,HUTCHMED (China) Limited,1458135000,America/New_York,EDT,-14400000,14.71,50.0,14.6,31.08,28.6,2.0,buy,10,858443008,5.06,-91185000,40147000,3.006,3.199,757235968,5.018,4.475,-0.04981,-0.03396,-271587000,-91008128,47663000,1.637,0.033469997,-0.12042,-0.13112001,USD,
2,Cheung Kong Center,48th Floor 2 Queen's Road,Central,Hong Kong,852 2121 8200,852 2128 1778,https://www.hutch-med.com,Drug Manufacturers—Specialty & Generic,Healthcare,"HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3'-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton's tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; HMPL-A83, an investigational IgG4-type humanized anti-CD47 monoclonal antibody; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. The company was incorporated in 2000 and is headquartered in Central, Hong Kong.",1990,"{'maxAge': 1, 'name': 'Mr. Chig Fung  Cheng BEc, CA', 'age': 55, 'title': 'CFO & Exec. Director', 'yearBorn': 1967, 'fiscalYear': 2022, 'totalPay': 886000, 'exercisedValue': 0, 'unexercisedValue': 0}",2,3,7,4,5,1693526400,1672444800,86400,2,14.7,14.89,14.56,15.025,14.7,14.89,14.56,15.025,0.0,0.872372,-14.144232,162843,162843,109469,97700,97700,14.5,14.78,1000,1100,2572484864,7.39,21.28,3.3972037,14.0608,14.5965,0.0,0.0,USD,1695426048,-0.03885,92471474,174198000,927979,1035902,1690761600,1693440000,0.0053,0.00413,0.14908,8.71,4.61,3.1908894,1672444800,1703980800,1688083200,-29423000,-0.25,-1.04,1:1,1559174400,2.239,-18.593,NMS,EQUITY,HCM,HCM,HUTCHMED (China) Limited,HUTCHMED (China) Limited,1458135000,America/New_York,EDT,-14400000,14.71,50.0,14.6,31.08,28.6,2.0,buy,10,858443008,5.06,-91185000,40147000,3.006,3.199,757235968,5.018,4.475,-0.04981,-0.03396,-271587000,-91008128,47663000,1.637,0.033469997,-0.12042,-0.13112001,USD,
3,Cheung Kong Center,48th Floor 2 Queen's Road,Central,Hong Kong,852 2121 8200,852 2128 1778,https://www.hutch-med.com,Drug Manufacturers—Specialty & Generic,Healthcare,"HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3'-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton's tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; HMPL-A83, an investigational IgG4-type humanized anti-CD47 monoclonal antibody; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. The company was incorporated in 2000 and is headquartered in Central, Hong Kong.",1990,"{'maxAge': 1, 'name': 'Ms. Edith  Shih BSE, C.S., CGP, EdM, FCIS, FCS, FCS(PE), M.A., MA', 'age': 70, 'title': 'Company Sec. & Non-Exec. Director', 'yearBorn': 1952, 'exercisedValue': 0, 'unexercisedValue': 0}",2,3,7,4,5,1693526400,1672444800,86400,2,14.7,14.89,14.56,15.025,14.7,14.89,14.56,15.025,0.0,0.872372,-14.144232,162843,162843,109469,97700,97700,14.5,14.78,1000,1100,2572484864,7.39,21.28,3.3972037,14.0608,14.5965,0.0,0.0,USD,1695426048,-0.03885,92471474,174198000,927979,1035902,1690761600,1693440000,0.0053,0.00413,0.14908,8.71,4.61,3.1908894,1672444800,1703980800,1688083200,-29423000,-0.25,-1.04,1:1,1559174400,2.239,-18.593,NMS,EQUITY,HCM,HCM,HUTCHMED (China) Limited,HUTCHMED (China) Limited,1458135000,America/New_York,EDT,-14400000,14.71,50.0,14.6,31.08,28.6,2.0,buy,10,858443008,5.06,-91185000,40147000,3.006,3.199,757235968,5.018,4.475,-0.04981,-0.03396,-271587000,-91008128,47663000,1.637,0.033469997,-0.12042,-0.13112001,USD,
4,Cheung Kong Center,48th Floor 2 Queen's Road,Central,Hong Kong,852 2121 8200,852 2128 1778,https://www.hutch-med.com,Drug Manufacturers—Specialty & Generic,Healthcare,"HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3'-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton's tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; HMPL-A83, an investigational IgG4-type humanized anti-CD47 monoclonal antibody; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. The company was incorporated in 2000 and is headquartered in Central, Hong Kong.",1990,"{'maxAge': 1, 'name': 'Dr. Karen Jane  Atkin', 'age': 56, 'title': 'Exec. VP & COO', 'yearBorn': 1966, 'exercisedValue': 0, 'unexercisedValue': 0}",2,3,7,4,5,1693526400,1672444800,86400,2,14.7,14.89,14.56,15.025,14.7,14.89,14.56,15.025,0.0,0.872372,-14.144232,162843,162843,109469,97700,97700,14.5,14.78,1000,1100,2572484864,7.39,21.28,3.3972037,14.0608,14.5965,0.0,0.0,USD,1695426048,-0.03885,92471474,174198000,927979,1035902,1690761600,1693440000,0.0053,0.00413,0.14908,8.71,4.61,3.1908894,1672444800,1703980800,1688083200,-29423000,-0.25,-1.04,1:1,1559174400,2.239,-18.593,NMS,EQUITY,HCM,HCM,HUTCHMED (China) Limited,HUTCHMED (China) Limited,1458135000,America/New_York,EDT,-14400000,14.71,50.0,14.6,31.08,28.6,2.0,buy,10,858443008,5.06,-91185000,40147000,3.006,3.199,757235968,5.018,4.475,-0.04981,-0.03396,-271587000,-91008128,47663000,1.637,0.033469997,-0.12042,-0.13112001,USD,
5,Cheung Kong Center,48th Floor 2 Queen's Road,Central,Hong Kong,852 2121 8200,852 2128 1778,https://www.hutch-med.com,Drug Manufacturers—Specialty & Generic,Healthcare,"HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3'-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton's tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; HMPL-A83, an investigational IgG4-type humanized anti-CD47 monoclonal antibody; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. The company was incorporated in 2000 and is headquartered in Central, Hong Kong.",1990,"{'maxAge': 1, 'name': 'Mr. Kin Hung  Lee M.B.A.', 'age': 45, 'title': 'Sr. VP of Corp. Fin. & Devel.', 'yearBorn': 1977, 'exercisedValue': 0, 'unexercisedValue': 0}",2,3,7,4,5,1693526400,1672444800,86400,2,14.7,14.89,14.56,15.025,14.7,14.89,14.56,15.025,0.0,0.872372,-14.144232,162843,162843,109469,97700,97700,14.5,14.78,1000,1100,2572484864,7.39,21.28,3.3972037,14.0608,14.5965,0.0,0.0,USD,1695426048,-0.03885,92471474,174198000,927979,1035902,1690761600,1693440000,0.0053,0.00413,0.14908,8.71,4.61,3.1908894,1672444800,1703980800,1688083200,-29423000,-0.25,-1.04,1:1,1559174400,2.239,-18.593,NMS,EQUITY,HCM,HCM,HUTCHMED (China) Limited,HUTCHMED (China) Limited,1458135000,America/New_York,EDT,-14400000,14.71,50.0,14.6,31.08,28.6,2.0,buy,10,858443008,5.06,-91185000,40147000,3.006,3.199,757235968,5.018,4.475,-0.04981,-0.03396,-271587000,-91008128,47663000,1.637,0.033469997,-0.12042,-0.13112001,USD,
6,Cheung Kong Center,48th Floor 2 Queen's Road,Central,Hong Kong,852 2121 8200,852 2128 1778,https://www.hutch-med.com,Drug Manufacturers—Specialty & Generic,Healthcare,"HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3'-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton's tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; HMPL-A83, an investigational IgG4-type humanized anti-CD47 monoclonal antibody; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. The company was incorporated in 2000 and is headquartered in Central, Hong Kong.",1990,"{'maxAge': 1, 'name': 'Mr. Charles George Rupert  Nixon', 'age': 52, 'title': 'Group Gen. Counsel', 'yearBorn': 1970, 'exercisedValue': 0, 'unexercisedValue': 0}",2,3,7,4,5,1693526400,1672444800,86400,2,14.7,14.89,14.56,15.025,14.7,14.89,14.56,15.025,0.0,0.872372,-14.144232,162843,162843,109469,97700,97700,14.5,14.78,1000,1100,2572484864,7.39,21.28,3.3972037,14.0608,14.5965,0.0,0.0,USD,1695426048,-0.03885,92471474,174198000,927979,1035902,1690761600,1693440000,0.0053,0.00413,0.14908,8.71,4.61,3.1908894,1672444800,1703980800,1688083200,-29423000,-0.25,-1.04,1:1,1559174400,2.239,-18.593,NMS,EQUITY,HCM,HCM,HUTCHMED (China) Limited,HUTCHMED (China) Limited,1458135000,America/New_York,EDT,-14400000,14.71,50.0,14.6,31.08,28.6,2.0,buy,10,858443008,5.06,-91185000,40147000,3.006,3.199,757235968,5.018,4.475,-0.04981,-0.03396,-271587000,-91008128,47663000,1.637,0.033469997,-0.12042,-0.13112001,USD,
7,Cheung Kong Center,48th Floor 2 Queen's Road,Central,Hong Kong,852 2121 8200,852 2128 1778,https://www.hutch-med.com,Drug Manufacturers—Specialty & Generic,Healthcare,"HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3'-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton's tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; HMPL-A83, an investigational IgG4-type humanized anti-CD47 monoclonal antibody; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. The company was incorporated in 2000 and is headquartered in Central, Hong Kong.",1990,"{'maxAge': 1, 'name': 'Ms. Selina  Zhang', 'title': 'Sr. VP of Global HR', 'exercisedValue': 0, 'unexercisedValue': 0}",2,3,7,4,5,1693526400,1672444800,86400,2,14.7,14.89,14.56,15.025,14.7,14.89,14.56,15.025,0.0,0.872372,-14.144232,162843,162843,109469,97700,97700,14.5,14.78,1000,1100,2572484864,7.39,21.28,3.3972037,14.0608,14.5965,0.0,0.0,USD,1695426048,-0.03885,92471474,174198000,927979,1035902,1690761600,1693440000,0.0053,0.00413,0.14908,8.71,4.61,3.1908894,1672444800,1703980800,1688083200,-29423000,-0.25,-1.04,1:1,1559174400,2.239,-18.593,NMS,EQUITY,HCM,HCM,HUTCHMED (China) Limited,HUTCHMED (China) Limited,1458135000,America/New_York,EDT,-14400000,14.71,50.0,14.6,31.08,28.6,2.0,buy,10,858443008,5.06,-91185000,40147000,3.006,3.199,757235968,5.018,4.475,-0.04981,-0.03396,-271587000,-91008128,47663000,1.637,0.033469997,-0.12042,-0.13112001,USD,
8,Cheung Kong Center,48th Floor 2 Queen's Road,Central,Hong Kong,852 2121 8200,852 2128 1778,https://www.hutch-med.com,Drug Manufacturers—Specialty & Generic,Healthcare,"HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3'-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton's tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; HMPL-A83, an investigational IgG4-type humanized anti-CD47 monoclonal antibody; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. The company was incorporated in 2000 and is headquartered in Central, Hong Kong.",1990,"{'maxAge': 1, 'name': 'Dr. Qingmei  Wang Ph.D.', 'age': 59, 'title': 'Sr. VP of Bus. Devel. & Strategic Alliances', 'yearBorn': 1963, 'exercisedValue': 0, 'unexercisedValue': 0}",2,3,7,4,5,1693526400,1672444800,86400,2,14.7,14.89,14.56,15.025,14.7,14.89,14.56,15.025,0.0,0.872372,-14.144232,162843,162843,109469,97700,97700,14.5,14.78,1000,1100,2572484864,7.39,21.28,3.3972037,14.0608,14.5965,0.0,0.0,USD,1695426048,-0.03885,92471474,174198000,927979,1035902,1690761600,1693440000,0.0053,0.00413,0.14908,8.71,4.61,3.1908894,1672444800,1703980800,1688083200,-29423000,-0.25,-1.04,1:1,1559174400,2.239,-18.593,NMS,EQUITY,HCM,HCM,HUTCHMED (China) Limited,HUTCHMED (China) Limited,1458135000,America/New_York,EDT,-14400000,14.71,50.0,14.6,31.08,28.6,2.0,buy,10,858443008,5.06,-91185000,40147000,3.006,3.199,757235968,5.018,4.475,-0.04981,-0.03396,-271587000,-91008128,47663000,1.637,0.033469997,-0.12042,-0.13112001,USD,
9,Cheung Kong Center,48th Floor 2 Queen's Road,Central,Hong Kong,852 2121 8200,852 2128 1778,https://www.hutch-med.com,Drug Manufacturers—Specialty & Generic,Healthcare,"HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3'-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton's tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; HMPL-A83, an investigational IgG4-type humanized anti-CD47 monoclonal antibody; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. The company was incorporated in 2000 and is headquartered in Central, Hong Kong.",1990,"{'maxAge': 1, 'name': 'Mr. Hong  Chen', 'age': 52, 'title': 'Sr. VP & Chief Commercial Officer- China', 'yearBorn': 1970, 'exercisedValue': 0, 'unexercisedValue': 0}",2,3,7,4,5,1693526400,1672444800,86400,2,14.7,14.89,14.56,15.025,14.7,14.89,14.56,15.025,0.0,0.872372,-14.144232,162843,162843,109469,97700,97700,14.5,14.78,1000,1100,2572484864,7.39,21.28,3.3972037,14.0608,14.5965,0.0,0.0,USD,1695426048,-0.03885,92471474,174198000,927979,1035902,1690761600,1693440000,0.0053,0.00413,0.14908,8.71,4.61,3.1908894,1672444800,1703980800,1688083200,-29423000,-0.25,-1.04,1:1,1559174400,2.239,-18.593,NMS,EQUITY,HCM,HCM,HUTCHMED (China) Limited,HUTCHMED (China) Limited,1458135000,America/New_York,EDT,-14400000,14.71,50.0,14.6,31.08,28.6,2.0,buy,10,858443008,5.06,-91185000,40147000,3.006,3.199,757235968,5.018,4.475,-0.04981,-0.03396,-271587000,-91008128,47663000,1.637,0.033469997,-0.12042,-0.13112001,USD,
